Led by Ajay Rana, professor of surgery at the UIC College of Medicine and member of the University of Illinois Cancer Center, the study describes the experiments and how the compound — called XP-524 — works. XP-524 alters two proteins involved in the formation of several tumor types — bromodomain and extra-terminal motif (BET) and histone acetyltransferase EP300/CBP (EP300). The compound blocks these proteins, which helps to reactivate immune responses to the most common type of pancreatic cancer, pancreatic ductal adenocarcinoma .Read more . . .
University of Illinois Chicago researchers have developed a compound that may one day offer hope for pancreatic cancer treatment. A pre-clinical study of the experimental compound shows that it more than doubles the average survival time for mice with pancreatic cancer, and that survival time was extended further when combined with immunotherapy.